PATENT—Fed. Cir.: Lupin’s generic doxycycline formulation does not infringe Galderma’s patents

Galderma responded by filing a lawsuit under the Hatch-Waxman Act, alleging infringement of the ‘532 and ‘740 patents. Galderma claimed that Lupin’s …